Evidence map›Paper›PMID 28135344›Full record

ArticlePloS one2017

Characterization of Putative Erythroid Regulators of Hepcidin in Mouse Models of Anemia.

Cornel S G Mirciov, Sarah J Wilkins, Linda A Dunn, Gregory J Anderson, David M Frazer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Iron Mining for Erythropoiesis.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Review
  9. Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis.Pharmaceuticals (Basel, Switzerland) · 2019
    Review
  10. Erythropoietic regulators of iron metabolism.Free radical biology & medicine · 2019
    Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Cornel S G MirciovIron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Sarah J WilkinsIron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Linda A DunnIron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Gregory J AndersonIron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
David M FrazerIron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
QIMR Berghofer Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron is crucial for many biological functions, but quantitatively the most important use of iron is in the production of hemoglobin in red blood cell precursors. The amount of iron in the plasma, and hence its availability for hemoglobin synthesis, is determined by the liver-derived iron regulatory hormone hepcidin. When the iron supply to erythroid precursors is limited, as often occurs during stimulated erythropoiesis, these cells produce signals to inhibit hepatic hepcidin production, thereby increasing the amount of iron that enters the plasma. How stimulated erythropoiesis suppresses hepcidin production is incompletely understood, but erythroferrone, Gdf15 and Twsg1 have emerged as candidate regulatory molecules. To further examine the relationship between erythropoiesis and the candidate erythroid regulators, we have studied five mouse models of anemia, including two models of β-thalassemia (Hbbth3/+ and RBC14), the hemoglobin deficit mouse (hbd), dietary iron deficient mice and mice treated with phenylhydrazine to induce acute hemolysis. Hematological parameters, iron status and the expression of Erfe (the gene encoding erythroferrone), Gdf15 and Twsg1 in the bone marrow and spleen were examined. Erfe expression was the most consistently upregulated of the candidate erythroid regulators in all of the mouse models examined. Gene expression was particularly high in the bone marrow and spleen of iron deficient animals, making erythroferrone an ideal candidate erythroid regulator, as its influence is strongest when iron supply to developing erythroid cells is limited. Gdf15 expression was also upregulated in most of the anemia models studied although the magnitude of the increase was generally less than that of Erfe. In contrast, very little regulation of Twsg1 was observed. These results support the prevailing hypothesis that erythroferrone is a promising erythroid regulator and demonstrate that Erfe expression is stimulated most strongly when the iron supply to developing erythroid cells is compromised.

Indexed as

AnemiaAnimalsDisease Models, AnimalErythroid Precursor CellsErythropoietinHepcidinsIronIron DeficienciesLiverMice, Inbred C57BLModels, GeneticPhenylhydrazinesReceptors, TransferrinErythropoietinHepcidinsIronphenylhydrazinePhenylhydrazinesReceptors, TransferrinTfrc protein, mouse

Identifiers

PMID28135344
PMCPMC5279787
OpenAlexW2581296921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.